Although human papillomavirus (HPV) vaccines offer enormous promise for the ultimate control and possible elimination of cervical cancer, barriers to uptake and coverage of the vaccine both in high-and low/middle-income settings mean that advances in secondary prevention continue to be essential to prevent unnecessary deaths and suffering from cervical cancer for decades to come. While cytology (the Pap smear) has reduced cervical cancer incidence and prevalence in jurisdictions where it has been systematically implemented in population-based programs-mainly in highincome settings-limitations inherent to this method, and to program delivery, leave many women still vulnerable to cervical cancer. Recent evidence has confirmed that screening based on HPV testing prevents more invasive cervical cancer and precancerous lesions, and offers innovative options such as self-collection of specimens to improve screening uptake broadly. In this paper, we review key advances, future opportunities, and ongoing challenges for secondary prevention of cervical cancer using HPV-based testing.
K E Y W O R D SCervical cancer; Eradication; HPV; Screening; Self-collection
| BACKGROUNDWith the approval of the 9-valent human papillomavirus (HPV) vaccine, we move a step closer to the elimination of cervical cancer. 1 However, elimination will only be possible with high rates of vaccine uptake for young girls across the globe, in all regions and countries. To date, addressing barriers to HPV vaccine uptake, such as acceptability, cost, and program infrastructure, remain a significant challenge for most countries, particularly in low-and middleincome countries (LMICs). A recent review of HPV vaccination found that globally, only 32.1% of girls aged 10-20 years in high-income settings and approximately 0.3% in low-and middle-income settings-where cervical cancer rates remain highest-have had an HPV vaccination series. 2 An additional challenge is that the vaccine prevents viral infection at relatively young ages, and this infection results in cancers that occur decades later. 3 Thus, any woman who did not receive the vaccine prior to infection with oncogenic HPV types may be at risk for developing cervical cancer, and she requires access to effective secondary prevention-i.e. screening, with treatment when needed. Without efforts to improve both the quality of, and access to, screening, it is estimated that the number of women developing cervical cancer annually worldwide will rise to more than 700 000 by 2030. 4 Therefore, improving secondary prevention of cervical cancer should remain a key priority for women's health globally for decades to come. Efforts need to focus on better access to, and improvements in, molecular platforms for detection of the HPV virus. In this paper, we describe recent advances in optimizing the effectiveness and access to secondary prevention for cervicalThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any med...